The ACP received funding to help interpret research and support decisions about MS treatments for older adults with MS.

IMP761 was well tolerated in healthy volunteers when given at single increasing doses, with no safety concerns, according to ...

Managing risk is part of everyday business. But how do you deal with fear? Fear management has been a key challenge at Biogen Idec for the past four years, since a few patients taking the company’s ...

Roche (OTCQX:RHHBY) shares closed ~4% higher in Europe on Monday as the maker of Ocrevus multiple sclerosis therapy announced two Phase 3 trial successes for fenebrutinib, its new experimental drug ...

A University of Toronto-led study has identified a possible biomarker linked to multiple sclerosis (MS) disease progression. The findings, validated in both mouse and in humans, could help to identify ...

Trial tests drug against relapsing form of the disease Drug candidate as effective as Roche's Ocrevus in a separate study Fenebrutinib could bring in over $1 billion in annual peak sales FRANKFURT, ...

Swiss pharmaceuticals powerhouse Roche announced on Saturday that the company’s experimental multiple sclerosis drug met its primary goal in a late-stage trial in patients with a rare form of the ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

The National Institute for Health and Care Excellence (NICE) has recommended natalizumab for treating adults with highly active relapsing-remitting multiple sclerosis (RRMS) whose disease has ...